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or inhibitors for the indicated times and concentrations under serum-free conditions. Cell viability was evaluated after all treatment conditions.
Preparation of DLPC Micelles
DLPC micelles were prepared in DMSO by sonication as previously described [15] . Purity of all phospholipids was >99%.
Quantification of nucleotide release
Nucleotide release from liver cells was quantified using the bioluminescent Enzylight TM ADP Assay Kit (BioAssay Systems, Hayward, CA) and manufacturer's recommended protocols. The assay utilizes luciferase to convert ATP and D-luciferin to oxyluciferin and light. ATP and ADP concentrations were quantified by subtraction, before and after conversion of ADP to ATP. Liver cell media aliquots were harvested from ~5 x 10 5 cells/well and then frozen at -20 o C. Samples were thawed immediately prior to the assay and 20 µl/well was transferred to a 96-well black luminometer plate. The luciferin-luciferase reagents were added to the samples and the luminescence was quantified in a luminometer (Promega Glomax, 96 well plate reader). Media nucleotide levels were unchanged after RT storage for 2h or -20 o C storage for 6 months.
Knockdown of Human P2Y13 by Small
Interference RNA HepG2 cells were transiently transfected with All Stars Negative control siRNA from Qiagen (Mississauga, ON) or two different P2Y 13 siRNA sequences (ACCUUCAUCAUCUACCUCAAAUU or GACACUCAUGCUUCCUUUCAAUU) from Thermo Scientific Dharmacon (Lafayette, CO), by reverse transfection using Lipofectamine 2000 (Invitrogen, Carlsbad, CA) in 12-well plates. In brief, complexes were prepared per manufacturer's specifications with a Lipofectamine 2000-to-siRNA volume-to-mole ratio of 2:40 (µL:ρmol) in 200µL of Opti-MEM I Reduced Serum Media (Invitrogen, Carlsbad, CA). LipofectaminesiRNA complexes were added to the cells immediately after the cells were seeded at a density of 500,000 cells/well in a volume of 1mL of normal growth media containing 10% FBS in the absence of penicillin/ streptomycin. The cells were treated with ADP or DLPC in serum-free DMEM 48h after transfection. Cell media and lysate samples were harvested at the indicated timepoints for immunoblot analysis. Transfection of the control and test siRNA caused no cytotoxic effects.
Overexpression of Human P2Y13 by Plasmid
The pCMV6 vector containing the full length human P2Y 13 cDNA was purchased from Origene (Rockville, MD). HepG2 cells were transiently transfected with control plasmid or the pCMV6-P2Y13 plasmid by reverse transfection using FuGENE HD (Roche Applied Science, Laval, QC). Complexes were prepared per manufacturer's instructions with a FuGENE HD-to-DNA volume-to-mass ratio of 6:2 (µL to µg) in 100µL of Opti-MEM I Reduced Serum Media (Invitrogen, Carlsbad, CA). HepG2 cells were trypsinized and seeded in 12-well plates at a density of 500,000 cells/well in a volume of 1mL in normal growth media containing 10% FBS in the absence of penicillin/streptomycin and then 50µL of the transfection complexes were immediately added to the suspended cells. The cells were treated with ADP or DLPC in serum-free DMEM 48h after transfection. Cell media and lysate samples were harvested at the indicated timepoints for immunoblot analysis. Transfection of the control and test plasmid caused no cytotoxic effects.
Immunoblot Analysis
After treatment for the indicated timepoints, cells were washed twice with ice-cold PBS. Cells were lysed in NP-40 lysis buffer (Biosource, Camarillo, CA) supplemented with 1mM PMSF and 1X protease inhibitor cocktail (Sigma, Saint Louis, MO). Cell protein concentrations were determined by the BCA Protein Assay (Thermo Fisher Scientific, Waltham, MA). Cell lysate samples containing equal total protein (30μg) were separated by SDS-PAGE and analyzed by Western blot using specific antibodies to HL, V5, and β-actin. Blots were exposed using the Alpha Innotech FluorChem TM HD Imager and band intensities were quantified with the Alpha Ease FC TM software.
HL-V5 Endocytosis Assay
HepG2 cells were transiently transfected with the pcDNA6-human HL-V5-6XHis plasmid construct obtained from Dr. Peterfy (UCLA, Los Angeles, CA) by reverse transfection using FuGENE HD (Roche Applied
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Science, Laval, QC) as described for P2Y 13 overexpression. The conditioned media containing the secreted HL-V5 was collected 48h after transfection and pooled. Wildtype (untransfected) HepG2 cells were either pre-treated with 100µM ADP or left untreated for 30min in serum-free DMEM. HL-V5 conditioned media was then added to the pre-treated cells for either 30min or 4h for endocytosis. Cells were then harvested to determine the total cell association or internalization of HL-V5. Cells for total cell association were washed gently in PBS and then lysed, whereas cells for internalization were acid washed twice with 150mM NaCl and 10mM acetic acid at pH 3.5 as previously described in [16] . Cell media and lysate samples were then immunoblotted and probed for V5.
Statistical Analysis
Values are shown as Mean ± SD for at least 3 independent experiments and P<0.05 was considered significant. Differences between mean values were evaluated by one-way analysis of variance (ANOVA) on ranks by a pairwise multiple comparison using the Student-Newman-Keuls post-hoc test (SigmaStat; Systat Software, Inc., San Jose, CA).
Results
Nucleotide release, autophagy and HL Extracellular nucleotides block HDL secretion from liver cells by stimulating autophagic proteolytic degradation pathways [10] . Autophagy is therefore affected by autocrine/ paracrine signaling and liver cells are known to release nucleotides into the extracellular space. Serum deprivation is well known to stimulate cellular autophagy [17, 18] and we now show that serum deprivation also stimulates nucleotide release from liver cells. Extracellular ADP levels may therefore play a role in the propagation of autophagy. Nucleotide levels in the media of confluent human liver cells were quantified by a bioluminescent Enzylight TM assay and shown to be in low [nM] , with basal nucleotide levels averaging ~15 nM (Fig. 1A) . A change in the culture medium to a media containing serum and glucose (1% FBS, 5 mM glucose) had little effect on extracellular ATP levels, but more than doubles ADP levels by 30 minutes. Changing the media to a serum deficient (no FBS, 5 mM glucose) media also has no effect on ATP, but increases ADP levels 8-fold (Fig. 1A) . Cellular levels of the autophagic marker protein, LC3-II, were unaffected when cell media contained serum, but increased 2.5-fold by 60 min when culture media was devoid of serum (Fig. 1B) . Depletion of media serum also completely blocked the release of HL from the liver cells and reduced intracellular HL levels by ~20% (Fig. 1C) .
HL release and cellular autophagy
Both HDL and HL release from liver cells appear to be blocked by a nucleotide induction of cellular autophagy. We previously showed that ADP acts through autophagic pathways to inhibit HDL secretion [10] and Fig. 2 shows that ADP stimulates autophagy and blocks HL release. Treatment of liver cells with ADP (100 µM) significantly increases LC3-II levels at 4 hours ( Fig. 2A) , blocks HL release and accumulation in the media at 24h, and inhibits the induction of HL release by DLPC (Fig. 2B) . ADP may therefore block HL release from liver cells by stimulating autophagic proteolytic degradation pathways. ADP stimulates autophagy and increases cellular LC3-II levels similar to the proteasomal inhibitor / autophagy stimulant, ALLN [10] . ALLN has a similar inhibitory effect on HL release as that observed with HDL. ALLN significantly reduced HL release at 4h (Fig. 3A) and reduced cellular HL levels by ~35% (Fig. 3B ). ADP and ALLN therefore stimulate autophagic degradation and decrease the total HL mass (media+cellular), in much the same manner to that previously reported for apoA-I [10] .
To determine how inhibition of autophagy may affect HL release, we evaluated the effect of the autophagy inhibitor, 3-methyladenine (3-MA). Treatment of liver cells with 3-MA (5 mM) significantly increased HL release after 4h, while treatment with both ADP and 3-MA blocked the HL release stimulatory effect of 3-MA (Fig. 4A) . Treatment with 3-MA also Fig. 1 . Serum deprivation stimulates nucleotide release and cellular autophagy and blocks HL release. Human liver cells were cultured to near confluence in nutrient complete media. The media was changed to a serum competent (+ FBS = 5 mM glucose, 1% FBS) and deficient media (-FBS = 5 mM glucose) and then media aliquots were sampled over time. (A) Media ATP&ADP concentrations were determined by bioluminescence assay and values are expressed as mean ± SD of 3 independent experiments. *P<0.01 vs control (t=0) **P<0.001 vs +FBS (t=0.5h) (B) Cell lysates were immunoblotted for LC3 and β-actin. Histograms represent band densitometry analysis of LC3-II concentration in the cell lysate normalized to β-actin and expressed as mean ± SD of 3 independent experiments. *P=0.05 vs. control (C) Cell lysates and conditioned media were collected after 2h and immunoblotted for HL. The immunoblots are representative of 3 independent experiments that were performed in triplicate. species of HL-V5, at 62 and 68 kDa and the V5 mAb detects both species equally (Fig. 6,  t=0) . We have previously shown that HepG2 cells secrete two isoforms of HL [21] and earlier studies suggest the proteins differ in their extent of glycosylation [22] . Figure 6 shows that only the 62kDa HL-V5 can become re-associated and taken up by the cell. The 62kDa HL-V5 is progressively internalized over time and after 24h the media becomes almost completely depleted of the protein (Fig. 6, upper panel) . Concomitantly, the 62kDa HL is selectively internalized into HepG2 cells and accumulates unmodified in the cell over 24h. Internalized 62kDa HL-V5 was not degraded over time, but was retained intact in the cell for 24h (Fig. 6 , lower panel). The effect of ADP on the metabolism of exogenous HL-V5 was then investigated. Treatment of HepG2 cells with 100µM ADP slightly reduced the total cell association of HL-V5 at 0.5h (Fig. 7A) , but had no effect on HL-V5 endocytosis. Treatment with ADP had no effect on the internalization of HL-V5 at 0.5h or 4h (Fig. 7A&B) . No HL-V5 degradation was detectable after short or long-term incubations for control or ADP treated cells. 
Discussion
Hypertriglyceridemia is a comorbidity of insulin resistance [1] and one that is thought to exacerbate perturbations in insulin signaling pathways that cause elevated blood glucose [23] . Elevations in blood triglyceride (TG) are a consequence of impaired TG-rich lipoprotein clearance [2] and over-production of VLDL [3] . Insulin resistance may also be associated with an increase in nucleotide release [24] [25] [26] . Increased circulating nucleotide levels may contribute to hypertriglyceridemia by increasing VLDL levels in the bloodstream [10, 11] . Gene knockout studies in mice have shown that a deficiency in the NTPDase1 can cause elevated blood nucleotide levels, insulin resistance and hypertriglyceridemia [11] .
VLDL-TG and apoB100 levels are elevated in insulin resistance [5, 7] and this may be partly a consequence of a stimulatory effect of extracellular nucleotides on hepatic VLDL secretion. Lipoprotein secretion is controlled by cellular proteolytic pathways and nucleotides act much like proteasomal inhibitors to block proteasomal degradation and stimulate autophagy [10] . Extracellular nucleotides, i.e. adenosine diphosphate (ADP), stimulate both apoB100 and apoE secretion from liver cells and thereby promote the accumulation of VLDL in the cell media [10] .
Nucleotides may also promote VLDL accumulation by blocking VLDL clearance from the bloodstream. Hepatic lipase (HL) promotes the hydrolysis and clearance of VLDL from the circulation and thereby regulates the production of LDL [4] . Circulatory VLDL levels are elevated in insulin resistance, as a consequence of reduced HL lipolytic function and impaired clearance of VLDL [5, 6] . We have previously shown that HL lipolytic function is regulated by HDL secretion from liver cells and by apolipoprotein exchange between HDL and VLDL [14] . HL release from liver cells is controlled by lysosomal degradation pathways [27] and therefore a nucleotide stimulation of autophagic-lysosomal degradation would be expected to reduce HL release (Fig. 8) . The data illustrated inFigures 1-5 appear to support this view.
We previously showed that exogenously applied nucleotides can stimulate autophagy and block protein secretion from liver cells [10] . In this study we have attempted to show that factors that increase nucleotide release and accumulation in the media also affect autophagy and protein secretion. Our data has identified a linkage between nucleotide release and cellular autophagy, which may suggest that autophagy is affected by autocrine/paracrine signaling. Nucleotide release is stimulated by factors that stress the cell, such as a serum deprivation in media, which stimulates the release of ADP (Fig. 1A) . ADP concentration doubles in the media after a change in media, but increases by orders of magnitude when media is deficient of FBS or other nutrients (data not shown). The ADP response to serum deprivation closely paralleled an autophagic response, as indicated by an increase in cellular LC3-II (Fig. 1B) . Increased ADP release and autophagy also directly parallel a reduction in HL release ( Figure 1C ). This is consistent with previous work, which has shown that autophagy inhibits protein secretion [17, 18] . However, while others have shown that serum deprivation initiates an autophagic response, this appears to be the first cited evidence that ADP release from a liver cell parallels the activation of autophagy. Further experimental work is needed to determine if extracellular nucleotides are required to promote an autocrine/paracrine modulation of cellular autophagy.
Exogenous nucleotides also block HL release. Treatment of human liver cells with ADP for 24h blocks both basal and DLPC-induced HL release (Fig. 2) , much the same as that observed with ADP on HDL secretion [10] . ADP significantly reduced cellular HL levels at 4h, much like the autophagic stimulator, ALLN (Fig. 3) , but only ALLN significantly reduced HL release at 4h. We have previously shown that incubations of >12 hours are usually required to show changes in HL release [13, 14] and since both ADP and ALLN had a more pronounced inhibitory effect on HDL secretion at 4h [10] , this may suggest that cellular transport pathways for HDL and HL may differ. Conversely, the autophagic inhibitor, 3-MA stimulates HL release from liver cells (Fig. 4A) and significantly increases HL levels in the cell (Fig. 4B) . This is strong evidence to suggest that HL release is sensitive to nucleotide-induced cellular autophagy and this may explain why chaperone proteins, i.e. lipase maturation factor 1, are needed to protect HL from lysosomal degradation during cellular transport [28] .
We showed that ADP acts through the membrane G-protein coupled receptor, P2Y 13 , to stimulate the autophagic degradation of apoA-I [10] . P2Y 13 expression was shown to directly correlate with LC3 expression. Since the metabolism of apoA-I in liver cells affects the release of HL [13] , it would be expected that ADP may also act through P2Y 13 to regulate HL release. In agreement with this view, P2Y 13 expression affects HL release in much the same manner as that shown for HDL (Fig. 5) . We previously showed that P2Y 13 gene silencing completely blocked the effect of ADP on cell signaling, autophagy and HDL secretion [10] . We now show that a reduction in P2Y 13 expression potently increases HL release by 5 to 8-fold, while P2Y 13 over-expression suppresses HL release (Fig. 5A&B) . It is notable that gene silencing had a much greater effect on HL release than over-expression of P2Y 13 . Similar observations were made between P2Y 13 expression and HDL secretion [10] . This appears consistent with the view that intracellular degradation pathways are normally hyperactive and most intracellular HL is targeted to degradation [27] . HL release may therefore be less sensitive to stimulation in autophagic degradation, but very sensitive to inhibition of degradation. Our work has clearly shown that P2Y 13 expression controls cellular autophagy by directly affecting LC3 levels [10] and this new work provides further evidence that P2Y 13 and autophagy regulate HL release (Fig. 8) .
To determine if purinergic stimulation of autophagy affects extracellular HL uptake and degradation, we utilized an epitope-labeled HL construct to characterize HL endocytic pathways. HL-V5 was produced in HepG2 cells [27] and then used to track the metabolism of extracellular HL in untransfected cells. HepG2 cells produce two HL-V5 isoforms at 62kDa and 68 kDa, but only the smaller 62 kDa species is taken up by the cell (Fig. 6) . HL-V5 is readily internalized into HepG2 cells, but ADP does not affect the endocytosis of HL-V5 (Fig.  6&7) . Nor did ADP affect the degradation of the endocytosed HL-V5. Proteins that were endocytosed in control and ADP treatment conditions remained intact in the HepG2 cells for up to 24h. The work suggests that HL release is not associated with extracellular HL recycling, but a consequence of autophagic degradation in lysosomes.
Elevated circulating nucleotide levels and purinergic activation in insulin resistance may therefore perturb triglyceride metabolism [10, 29] . Circulating nucleotide levels are affected by nucleotide degradative enzymes and therefore, altered function of cellular nucleotidases may be implicated in insulin resistance and hyperlipidemia. Polymorphisms in the endonucleotidase, CD39, gene were shown to be associated with type 2 diabetes and diabetic nephropathy [12] . A suppression in CD39 expression was also shown to cause insulin resistance and hypertriglyceridemia in mice [11] . These studies support the view that abnormal purinergic signaling may contribute to insulin resistance and hypertriglyceridemia [29] . Purinergic inhibitors may therefore have therapeutic value to treat metabolic and cardiovascular disease [30, 31] . Inhibition of P2Y 12 -dependent purinergic signaling pathways has shown significant cardiovascular therapeutic value [32, 33] .
